search
Back to results

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Primary Purpose

Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm

Status
Active
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Pelabresib (CPI-0610)
Ruxolitinib
Sponsored by
Constellation Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myelofibrosis focused on measuring Phase 1, Phase 2, Oncology, BET Inhibitor, Ruxolitinib, Pelabresib

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Phase 2 part: Patients with confirmed diagnosis of MF who meet all of the following criteria:

  • ANC ≥ 1 x 10^9/L without the assistance of granulocyte growth factors
  • Peripheral blood blast count <10%
  • ECOG performance status ≤ 2.
  • Adequate hematological, renal, hepatic, and coagulation laboratory assessments
  • No prior treatment with a BET inhibitor
  • Patients must give written informed consent to participate in this study before the performance of any study-related procedure.

For Arm 1 and 2 the following criteria should be considered:

  • Patients with confirmed diagnosis of MF who meet all of the following criteria
  • Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher
  • Spleen volume ≥ 450 cm^3 by MRI or CT for Cohorts 1B and 2B OR RBC transfusion dependent (defined as an average of ≥2 units of RBC transfusions per month over the 12 weeks prior to enrollment for Cohorts 1A and 2A)
  • At least 2 symptoms measurable (Score ≥ 1) using the Myelofibrosis Symptom Assessment Form Version 4.0 (MFSAF v4.0)
  • Platelet count ≥ 75 x 10^9/L without the assistance of thrombopoietic factors or transfusions for at least 14 days

Monotherapy Arm (Arm 1): Previously treated with a JAK inhibitor and be intolerant, resistant, refractory, or lost response to the JAK inhibitor; have not received the JAK inhibitor within 2 weeks prior to the start of study drug, or are ineligible to be treated with a JAK inhibitor

Combination Arm (Arm 2): Must have received single agent ruxolitinib and be on a stable dose for a minimum 8 weeks but have disease that is not being adequately controlled by ruxolitinib

For Arm 3 (JAK inhibitors naïve) the following criteria should be considered:

  • Patients with confirmed diagnosis of MF who meet all of the following criteria
  • Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher
  • Platelet count ≥ 100 x 10^9/L without the assistance of thrombopoietic factors or transfusions
  • Spleen volume ≥ 450 cm^3 by MRI/CT
  • At least 2 symptoms measurable (Score ≥ 3) or a total score of ≥ 10 using the MFSAF v4.0
  • No prior treatment with JAKi allowed

For Arm 4 (ET Expansion) the following criteria should be considered:

  • Patients with a confirmed diagnosis of ET
  • High-risk disease, defined as meeting at least one of the following criteria:
  • Age > 60 years
  • Platelet count > 1500 × 10^9/L (at any point during the patient's disease)
  • Previously documented thrombosis, erythromelalgia, or migraine
  • Previous hemorrhage related to ET
  • Diabetes or hypertension requiring pharmacological therapy for > 6 months
  • Have ≥2 symptoms with an average score ≥ 3 over the 7-day period prior to Cycle 1 Day 1 or an average total score of ≥15 over the 7-day period prior to Cycle 1 Day 1 using the using the MPN SAF

    • Platelets > 600 × 10^9/L
    • Resistant or intolerant to HU

Exclusion Criteria:

  • Current known active or chronic infection with human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C.
  • Impaired cardiac function or clinically significant cardiac diseases
  • Patients with Child-Pugh Class B or C
  • Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of CPI-0610 and/or ruxolitinib, including any unresolved nausea, vomiting, or diarrhea that is CTCAE Grade >1
  • Prior treatment with a BET inhibitor.
  • Pregnant or lactating women
  • Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study
  • Patients unwilling or unable to comply with this study protocol.

Sites / Locations

  • Mayo Clinic Arizona
  • UCLA Medical Center
  • Mayo Clinic Jacksonville
  • Northwestern University - Lurie Comprehensive Cancer Center
  • Massachusetts General Hospital Cancer Center
  • University of Michigan Medical Center
  • Washington University School of Medicne Neuromuscular Division Department of Neurology Research
  • Memorial Sloan Kettering Cancer Center
  • ICAHN School of Medicine at Mount Sinai
  • Weill Medical College and New York Presbyterian Hospital
  • The University of Texas MD Anderson Cancer Center
  • Froedtert & Medical College of Wisconsin
  • UZ Leuven - Campus Gasthuisberg
  • AZ Sint-Jan Burgge-Oostende AV- Campus Sint-Jan
  • ZNA Stuyvenberg Antwerpen
  • University of Alberta Hospital
  • St. Paul's Hospital
  • Juravinski Cancer Centre
  • Princess Margaret Cancer Centre
  • Jewish General Hospital
  • Institut de cancérologie du Gard - Hematologie clinique
  • CHRU de Lille - Hopital Claude Huriez
  • Institut Gustave Roussy
  • CHRU de Lille - Hopital Claude Huriez - Maladies du Sang
  • CHU - Hopital Saint Louis - Centre D'Investigations Clinique
  • Universitätsklinikum Bonn
  • Universitätsklinikum Leipzig AöR
  • Institue of Hematology "L. and A. Seràgnoli"
  • Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale (AUSL) di Rimini - Ospedale Infermi di Rimini
  • AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
  • Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda
  • IRCCS Policlinico San Matteo, Università degli studi di Pavi
  • Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon
  • Azienda Ospedaliero-Universitaria Careggi
  • AOU Maggiore della Carità
  • Maastricht University Medical Center
  • VUmcResearch B.V.
  • Erasmus Universitair Medisch Centrum Rotterdam
  • Instytut Hematologii i Transfuzjologii w Warszawie
  • Uniwersyteckie Centrum Kliniczne
  • Oxford University Hospitals
  • Belfast City Hospital
  • University of Cambridge
  • University Hospital of Wales
  • Beatson West of Scotland Cancer Centre
  • University College London Hospital's NHS foundation Trust
  • Guys and St Thomas' Hospital - Haematology
  • The Christie Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm (MF patients treated with pelabresib alone)

Arm 2: Prior JAKi Combination Arm

Arm 3: JAKi Naïve Combination Arm

Arm 4: Essential Thrombocythemia (ET) Monotherapy Arm

Arm Description

Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi (pelabresib alone) Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)

Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib (pelabresib + Ruxolitinib) Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)

Open to patients with MF who have not previously received a JAKi (pelabresib + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher

Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)

Outcomes

Primary Outcome Measures

Phase 2 (Cohorts 1B and 2B and Arm 3): Evaluate the spleenic response
Phase 2 (Cohorts 1A and 2A): Evaluate the RBC (Red Blood Cell) transfusion independence rate
Phase 2 (Arm 4): Evaluate the complete hematological response rate

Secondary Outcome Measures

Phase 2 (Arms 1, 2, and 3): Evaluate the duration of the spleenic response by imaging
Phase 2 (all arms): Evaluate the change in patient reported outcomes
Phase 2 (all arms): area under the curve (AUC)
Phase 2 (all arms): maximum observed plasma concentration (Cmax)

Full Information

First Posted
June 5, 2014
Last Updated
December 5, 2022
Sponsor
Constellation Pharmaceuticals
Collaborators
The Leukemia and Lymphoma Society
search

1. Study Identification

Unique Protocol Identification Number
NCT02158858
Brief Title
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Official Title
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 29, 2014 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Constellation Pharmaceuticals
Collaborators
The Leukemia and Lymphoma Society

4. Oversight

5. Study Description

Brief Summary
Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS), Preleukemia, Primary Myelofibrosis, Myeloproliferative Disorders, Bone Marrow Disease, Hematological Disease, Precancerous Conditions, Neoplasms, Leukemia, Neoplasms by Histologic Type, Essential Thrombocytosis
Keywords
Phase 1, Phase 2, Oncology, BET Inhibitor, Ruxolitinib, Pelabresib

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
341 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm (MF patients treated with pelabresib alone)
Arm Type
Experimental
Arm Description
Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi (pelabresib alone) Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)
Arm Title
Arm 2: Prior JAKi Combination Arm
Arm Type
Experimental
Arm Description
Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib (pelabresib + Ruxolitinib) Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)
Arm Title
Arm 3: JAKi Naïve Combination Arm
Arm Type
Experimental
Arm Description
Open to patients with MF who have not previously received a JAKi (pelabresib + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher
Arm Title
Arm 4: Essential Thrombocythemia (ET) Monotherapy Arm
Arm Type
Experimental
Arm Description
Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)
Intervention Type
Drug
Intervention Name(s)
Pelabresib (CPI-0610)
Intervention Type
Drug
Intervention Name(s)
Ruxolitinib
Primary Outcome Measure Information:
Title
Phase 2 (Cohorts 1B and 2B and Arm 3): Evaluate the spleenic response
Time Frame
By imaging after 24 weeks
Title
Phase 2 (Cohorts 1A and 2A): Evaluate the RBC (Red Blood Cell) transfusion independence rate
Time Frame
Absence of RBC transfusion and no hemoglobin level below 8 g/dL in the prior 12 weeks
Title
Phase 2 (Arm 4): Evaluate the complete hematological response rate
Time Frame
1 cycle (21 days)
Secondary Outcome Measure Information:
Title
Phase 2 (Arms 1, 2, and 3): Evaluate the duration of the spleenic response by imaging
Time Frame
Through study completion or end of treatment, up to 24 weeks and beyond
Title
Phase 2 (all arms): Evaluate the change in patient reported outcomes
Time Frame
Changes from baseline in the total symptom score (MFSAF v4.0) and PGIC after 24 weeks
Title
Phase 2 (all arms): area under the curve (AUC)
Time Frame
Assessed during Cycle 1 (first 21 days on study)
Title
Phase 2 (all arms): maximum observed plasma concentration (Cmax)
Time Frame
Assessed during Cycle 1 (first 21 days on study)
Other Pre-specified Outcome Measures:
Title
Phase 2 (Arms 1, 2, and 3): Evaluate response category rate
Time Frame
Rate of response by the International Working Group - Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria after 24 weeks
Title
Phase 2 (Arms 1, 2, and 3): Evaluate the rate of RBC transfusion and the RBC transfusion dependence rate
Time Frame
Average number of RBC units per subject-month, up to 24 weeks and beyond

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Phase 2 part: Patients with confirmed diagnosis of MF who meet all of the following criteria: ANC ≥ 1 x 10^9/L without the assistance of granulocyte growth factors Peripheral blood blast count <10% ECOG performance status ≤ 2. Adequate hematological, renal, hepatic, and coagulation laboratory assessments No prior treatment with a BET inhibitor Patients must give written informed consent to participate in this study before the performance of any study-related procedure. For Arm 1 and 2 the following criteria should be considered: Patients with confirmed diagnosis of MF who meet all of the following criteria Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher Spleen volume ≥ 450 cm^3 by MRI or CT for Cohorts 1B and 2B OR RBC transfusion dependent (defined as an average of ≥2 units of RBC transfusions per month (total of greater than 6 RBC transfusions) over the 12 weeks prior to enrollment for Cohorts 1A and 2A) At least 2 symptoms measurable (Score ≥ 1) using the Myelofibrosis Symptom Assessment Form Version 4.0 (MFSAF v4.0) Platelet count ≥ 75 x 10^9/L without the assistance of thrombopoietic factors or transfusions for at least 14 days Arm (Arm 1): Previously treated with a JAK inhibitor and be intolerant, resistant, refractory, or lost response to the JAK inhibitor; have not received the JAK inhibitor within 2 weeks prior to the start of study drug, or are ineligible to be treated with a JAK inhibitor Combination Arm (Arm 2): Must have received single agent ruxolitinib and be on a stable dose for a minimum 8 weeks but have disease that is not being adequately controlled by ruxolitinib For Arm 3 (JAK inhibitors naïve) the following criteria should be considered: Patients with confirmed diagnosis of MF who meet all of the following criteria Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-2 or higher Platelet count ≥ 100 x 10^9/L without the assistance of thrombopoietic factors or transfusions Spleen volume ≥ 450 cm^3 by MRI/CT At least 2 symptoms measurable (Score ≥ 3) or a total score of ≥ 10 using the Myelofibrosis Symptom Assessment Form Version 4.0 ( MFSAF v4.0) No prior treatment with JAKi allowed For Arm 4 (ET Expansion) the following criteria should be considered: Patients with a confirmed diagnosis of ET High-risk disease, defined as meeting at least one of the following criteria: Age > 60 years Platelet count > 1500 × 10^9/L (at any point during the patient's disease) Previously documented thrombosis, erythromelalgia, or migraine Previous hemorrhage related to ET Diabetes or hypertension requiring pharmacological therapy for > 6 months Have ≥2 symptoms with an average score ≥ 3 over the 7-day period prior to Cycle 1 Day 1 or an average total score of ≥15 over the 7-day period prior to Cycle 1 Day 1 using the using the MPN SAF Platelets > 600 × 10^9/L Resistant or intolerant to HU Exclusion Criteria: Current known active or chronic infection with human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C. Impaired cardiac function or clinically significant cardiac diseases Patients with Child-Pugh Class B or C Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of pelabresib and/or ruxolitinib, including any unresolved nausea, vomiting, or diarrhea that is CTCAE Grade >1 Prior treatment with a BET inhibitor. Pregnant or lactating women Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study Patients unwilling or unable to comply with this study protocol.
Facility Information:
Facility Name
Mayo Clinic Arizona
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Facility Name
UCLA Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Mayo Clinic Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Northwestern University - Lurie Comprehensive Cancer Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Massachusetts General Hospital Cancer Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
University of Michigan Medical Center
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Washington University School of Medicne Neuromuscular Division Department of Neurology Research
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
ICAHN School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Weill Medical College and New York Presbyterian Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Froedtert & Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
UZ Leuven - Campus Gasthuisberg
City
Leuven
State/Province
Viaams Braban
ZIP/Postal Code
3000
Country
Belgium
Facility Name
AZ Sint-Jan Burgge-Oostende AV- Campus Sint-Jan
City
Brugge
State/Province
West-Vlaanderen
ZIP/Postal Code
8000
Country
Belgium
Facility Name
ZNA Stuyvenberg Antwerpen
City
Antwerpen
ZIP/Postal Code
2060
Country
Belgium
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2G3
Country
Canada
Facility Name
St. Paul's Hospital
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6Z 2A5
Country
Canada
Facility Name
Juravinski Cancer Centre
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8V 5C2
Country
Canada
Facility Name
Princess Margaret Cancer Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Facility Name
Institut de cancérologie du Gard - Hematologie clinique
City
Nîmes
State/Province
Gard
ZIP/Postal Code
30029
Country
France
Facility Name
CHRU de Lille - Hopital Claude Huriez
City
Toulouse
State/Province
Haute-Garonne
ZIP/Postal Code
31059
Country
France
Facility Name
Institut Gustave Roussy
City
Villejuif
State/Province
Ile-de-France
ZIP/Postal Code
94805
Country
France
Facility Name
CHRU de Lille - Hopital Claude Huriez - Maladies du Sang
City
Lille
State/Province
Nord-Pas-de-Calais
ZIP/Postal Code
59037
Country
France
Facility Name
CHU - Hopital Saint Louis - Centre D'Investigations Clinique
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Universitätsklinikum Bonn
City
Bonn
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
53127
Country
Germany
Facility Name
Universitätsklinikum Leipzig AöR
City
Leipzig
State/Province
Sachsen
ZIP/Postal Code
04103
Country
Germany
Facility Name
Institue of Hematology "L. and A. Seràgnoli"
City
Bologna
State/Province
Emilia-Romagna
ZIP/Postal Code
40138
Country
Italy
Facility Name
Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale (AUSL) di Rimini - Ospedale Infermi di Rimini
City
Rimini
State/Province
Emilia-Romagna
ZIP/Postal Code
47923
Country
Italy
Facility Name
AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
City
Genova
State/Province
Liguria
ZIP/Postal Code
16132
Country
Italy
Facility Name
Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20122
Country
Italy
Facility Name
IRCCS Policlinico San Matteo, Università degli studi di Pavi
City
Pavia
State/Province
Lombardia
ZIP/Postal Code
27100
Country
Italy
Facility Name
Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon
City
Varese
State/Province
Lombardia
ZIP/Postal Code
21100
Country
Italy
Facility Name
Azienda Ospedaliero-Universitaria Careggi
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Facility Name
AOU Maggiore della Carità
City
Novara
ZIP/Postal Code
28100
Country
Italy
Facility Name
Maastricht University Medical Center
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 HX
Country
Netherlands
Facility Name
VUmcResearch B.V.
City
Amsterdam
State/Province
Noord-Holland
ZIP/Postal Code
1081 HV
Country
Netherlands
Facility Name
Erasmus Universitair Medisch Centrum Rotterdam
City
Rotterdam
State/Province
Zuid-Holland
ZIP/Postal Code
3015 AA
Country
Netherlands
Facility Name
Instytut Hematologii i Transfuzjologii w Warszawie
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-776
Country
Poland
Facility Name
Uniwersyteckie Centrum Kliniczne
City
Gdańsk
State/Province
Pomorskie
ZIP/Postal Code
80-952
Country
Poland
Facility Name
Oxford University Hospitals
City
Headington
State/Province
Oxford
ZIP/Postal Code
OX3 7LE
Country
United Kingdom
Facility Name
Belfast City Hospital
City
Belfast
ZIP/Postal Code
BT9 7AB
Country
United Kingdom
Facility Name
University of Cambridge
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Facility Name
University Hospital of Wales
City
Cardiff
ZIP/Postal Code
CF14 4XW
Country
United Kingdom
Facility Name
Beatson West of Scotland Cancer Centre
City
Glasgow
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Facility Name
University College London Hospital's NHS foundation Trust
City
London
ZIP/Postal Code
NW1 2PG
Country
United Kingdom
Facility Name
Guys and St Thomas' Hospital - Haematology
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
The Christie Hospital
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
36163997
Citation
Zavidij O, Haradhvala NJ, Meyer R, Cui J, Verstovsek S, Oh S, Mead A, Taverna P. MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S331-S332. doi: 10.1016/S2152-2650(22)01448-3.
Results Reference
derived

Learn more about this trial

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

We'll reach out to this number within 24 hrs